Adalimumab Expectations Revised In The Wake Of Amgen Launch
Analysts Outline Predictions And Weigh In On Key Questions Yet To Be Answered
The launch of Amgen’s Amjevita, the first US biosimilar rival to Humira, has been accompanied by multiple fresh forecasts of how competition could play out this year, with a host of further biosimilar launches on the horizon.
